Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men

Irie J, Inagaki E, Fujita M, Nakaya H, Mitsuishi M, Yamaguchi S, et al. | Endocrine Journal | 2020 | Evidence: limited

View on PubMed → | DOI | Publisher

Plain-language summary

Published 2020 in Endocrine Journal, this work by Irie J and collaborators tackles a specific question within safety-focused NMN/NAD+ research.

Key findings reported by the authors

Single oral doses of 100, 250, 500 mg NMN tolerated without adverse events in 10 men
Plasma NMN metabolites rose dose-dependently
First Japanese human safety study

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to safety decisions, with secondary relevance to dosage. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.

Where we cite this paper

← Back to research index